Cargando…

A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics

BACKGROUND: Gastric cancer (GC) is one of the leading causes of cancer deaths with high heterogeneity. There is currently a paucity of clinically applicable molecular classification system to guide precise medicine. METHODS: A total of 70 Chinese patients with GC were included in this study and whol...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haiyong, Ding, Yongfeng, Chen, Yanyan, Jiang, Junjie, Chen, Yiran, Lu, Jun, Kong, Mei, Mo, Fan, Huang, Yingying, Zhao, Wenyi, Fang, Ping, Chen, Xiangliu, Teng, Xiaodong, Xu, Nong, Lu, Yimin, Yu, Xiongfei, Li, Zhongqi, Zhang, Jing, Wang, Haohao, Bao, Xuanwen, Zhou, Donghui, Chi, Ying, Zhou, Tianhua, Zhou, Zhan, Chen, Shuqing, Teng, Lisong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502137/
https://www.ncbi.nlm.nih.gov/pubmed/34095982
http://dx.doi.org/10.1007/s10120-021-01201-9
Descripción
Sumario:BACKGROUND: Gastric cancer (GC) is one of the leading causes of cancer deaths with high heterogeneity. There is currently a paucity of clinically applicable molecular classification system to guide precise medicine. METHODS: A total of 70 Chinese patients with GC were included in this study and whole-exome sequencing was performed. Unsupervised clustering was undertaken to identify genomic subgroups, based on mutational signature, copy number variation, neoantigen, clonality, and essential genomic alterations. Subgroups were characterized by clinicopathological factors, molecular features, and prognosis. RESULTS: We identified 32 significantly mutated genes (SMGs), including TP53, ARID1A, PIK3CA, CDH1, and RHOA. Of these, PREX2, PIEZO1, and FSIP2 have not been previously reported in GC. Using a novel genome-based classification method that integrated multidimensional genomic features, we categorized GC into four subtypes with distinct clinical phenotypes and prognosis. Subtype 1, which was predominantly Lauren intestinal type, harbored recurrent TP53 mutation and ERBB2 amplification, high tumor mutation burden (TMB)/tumor neoantigen burden (TNB), and intratumoral heterogeneity, with a liver metastasis tendency. Subtype 2 tended to occur at an elder age, accompanying with frequent TP53 and SYNE1 mutations, high TMB/TNB, and was associated with poor prognosis. Subtype 3 and subtype 4 included patients with mainly diffuse/mixed type tumors, high frequency of peritoneal metastasis, and genomical stability, whereas subtype 4 was associated with a favorable prognosis. CONCLUSIONS: By integrating multidimensional genomic characteristics, we proposed a novel genomic classification system of GC associated with clinical phenotypes and provided a new insight to facilitate genome-guided risk stratification and disease management. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10120-021-01201-9.